Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities

Author's Avatar
Apr 27, 2022
  • Board Member/Acting CEO Provides Shareholder Update
  • Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation.
  • Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs